Ontozry (Cenobamate)

Cenobamate, the active ingredient in Ontozry, is an antiepileptic presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset seizures in adults with epilepsy, helping to reduce seizure frequency when added to existing antiepileptic regimens.

GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers. The company ensures product quality through stringent quality‑control processes and compliance with EU standards.

Ontozry (cenobamate) is indicated for the adjunctive treatment of partial‑onset seizures, a type of focal epilepsy.

Partial‑onset seizures (adult epilepsy): reduces seizure frequency as add‑on therapy. Focal seizures (adults): improves overall seizure control when combined with other antiepileptics. Epilepsy (adult patients): enhances therapeutic response as adjunctive medication.

Cenobamate may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - Drug reaction with eosinophilia and systemic symptoms (DRESS) - Severe skin reactions such as Stevens‑Johnson syndrome - Hyponatremia or significant hepatic enzyme elevations

When prescribing cenobamate, several safety considerations should be observed.

Dose titration: initiate at low dose and increase gradually under medical supervision. Cardiac monitoring: monitor for QT interval changes in patients with cardiac risk. Hepatic function: assess liver enzymes before and during therapy. Concomitant CNS depressants: use caution as additive sedation may occur. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Cenobamate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce cenobamate plasma levels. - Concomitant use with other sodium channel blockers at high doses (e.g., lamotrigine): increased risk of CNS depression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may increase cenobamate exposure. - Other GABA‑A modulators (e.g., benzodiazepines): may enhance sedation. - Alcohol: may potentiate CNS depressive effects.